Investors
Corporate Profile
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic and autologous CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.
Investors Kit
Corporate Presentation
Chairman's Letter 2020
Annual Report 2019
Financial Calendar
May 7, 2020
Q1 2020 Financial Results
Aug 6, 2020
H1 2020 Financial Results
Sep 28, 2020
R&D Day at Nasdaq
Nov 10, 2020
Q3 2020 Financial Results